<DOC>
	<DOCNO>NCT00640926</DOCNO>
	<brief_summary>The purpose study determine whether RX-1741 , oxazolidinone antibiotic , safe effective treatment mild moderate community acquire pneumonia ( CAP ) .</brief_summary>
	<brief_title>Safety Efficacy Study Oxazolidinone Treat Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Radezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Adult patient mild moderate CAP . Adult men woman ≥18 year . Females must postmenopausal least 1 year surgically sterile ( hysterectomy tubal ligation ) . Sexually active male must use barrier method birth control 30 day study . Their female partner also use additional reliable method contraception 30 day study . The patient must present acute respiratory illness ( ≤7 day duration ) history physical examination consistent diagnosis CAP . Patients require immediate study drug therapy serology culture result know may enter presumptive diagnosis CAP base : A chest radiograph baseline , show new infiltrate ( ) consistent pneumonia interpret radiologist investigator subsequently confirm radiologist . AND least 2 follow sign symptom : New increase cough . Purulent sputum change sputum character . Auscultatory finding consistent pneumonia . New onset progressive dyspnea tachypnea . Fever &gt; 38ºC oral &gt; 38.5ºC tympanic . White blood cell ( WBC ) count great 10,000 cells/mm3 &gt; 15 % immature neutrophil ( band ) , regardless total peripheral WBC count , less 4,500 cells/mm3 . Patient must able swallow large capsule intact . A write , voluntarily sign informed consent must obtain patient prior initiation studyrelated procedure . Hypersensitivity linezolid . Patients exclude take oral parenteral antibiotic follow : longacting penicillin within 28 day enrollment azithromycin , ceftriaxone , telithromycin within 14 day prior enrollment antibiotic &gt; 24 hour within 3 day enrollment Require parenteral antibiotic treatment CAP . Patient hospitalize resided longterm facility least 14 day onset symptom . Evidence pulmonary disease preclude evaluation therapeutic response . Patients know bronchial obstruction history postobstructive pneumonia . ( This exclude patient chronic obstructive pulmonary disease ) . Experienced recent clinically significant coagulopathy . History cystic fibrosis , active tuberculosis , meningitis , endocarditis , osteomyelitis . Immunocompromised patient include , limited patient CD4+ cell count &lt; 350 cells/mm3 secondary human immunodeficiency virus ( HIV ) infection , neutropenic patient granulocytes &lt; 1000/mm3 immunosuppression secondary drug corticosteroid therapy ( &gt; 10 mg/day prednisone equivalent least past 3 month ) , splenectomized patient patient know hyposplenia asplenia . Patients severe liver disease . Treatment investigational drug within 4 week prior study drug administration . Any underlying condition disease state would interfere completion study procedure evaluation absorption study drug . Patients bronchiectasis history recent respiratory infection cause Pseudomonas aeruginosa . Any infection require use concomitant antimicrobial agent , addition study drug . Patients take serotonergic agent , selective serotonin reuptake inhibitor ( SSRIs ) monoamine oxidase inhibitor ( MAOIs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>